A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
University of Wisconsin, Madison
Mclean Hospital
Inmune Bio, Inc.
Exelixis
National Institutes of Health Clinical Center (CC)
University of Pittsburgh
Incyte Corporation
Shuttle Pharmaceuticals, Inc.
Yale University
Geisinger Clinic
University of Kentucky
European Organisation for Research and Treatment of Cancer - EORTC
Wake Forest University Health Sciences
Day One Biopharmaceuticals, Inc.
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
Massachusetts General Hospital
Telix Pharmaceuticals (Innovations) Pty Limited
M.D. Anderson Cancer Center
AHS Cancer Control Alberta
Dana-Farber Cancer Institute
Biogen
University of Oklahoma
Children's Hospital Medical Center, Cincinnati
Alaunos Therapeutics
Medical College of Wisconsin
University Hospital Muenster
Australian & New Zealand Children's Haematology/Oncology Group
Rabin Medical Center
Alliance for Clinical Trials in Oncology
Jazz Pharmaceuticals
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Beijing Sanbo Brain Hospital
Wake Forest University Health Sciences
University Medical Center Groningen
University of Virginia
University College, London
Xoft, Inc.
St. Joseph's Hospital and Medical Center, Phoenix
Duke University
Hoosier Cancer Research Network
Jonsson Comprehensive Cancer Center
Instituto Nacional de Cancerologia de Mexico
Technical University of Munich
Technische Universität Dresden
OHSU Knight Cancer Institute
Hoffmann-La Roche
AC Camargo Cancer Center